Home » Stocks » CDNA

CareDx, Inc. (CDNA)

Stock Price: $79.26 USD 0.23 (0.29%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
Pre-market: $80.00 +0.74 (0.93%) Feb 26, 7:02 AM
Market Cap 4.01B
Revenue (ttm) 192.19M
Net Income (ttm) -18.71M
Shares Out 46.48M
EPS (ttm) -0.45
PE Ratio n/a
Forward PE n/a
Dividend $1.58
Dividend Yield 1.99%
Trading Day February 25
Last Price $79.26
Previous Close $79.03
Change ($) 0.23
Change (%) 0.29%
Day's Open 79.04
Day's Range 76.55 - 82.53
Day's Volume 1,855,134
52-Week Range 13.04 - 99.83

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 week ago

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...

GlobeNewsWire - 2 weeks ago

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...

GlobeNewsWire - 3 weeks ago

CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster Presentation at Upcoming TCT Meeting CareDx and Atara Biotherapeutics' AlloCell Partnership Highlighted in Poster P...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of ...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of ...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of ...

GlobeNewsWire - 1 month ago

Acquisition will build on CareDx's digital capabilities and continue deepening the moat with transplant centers Acquisition will build on CareDx's digital capabilities and continue deepening t...

GlobeNewsWire - 1 month ago

CareDx Shares Latest Clinical Data at the 21st Annual American Society of Transplant Surgeons Digital Winter Symposium CareDx Shares Latest Clinical Data at the 21st Annual American Society of...

GlobeNewsWire - 1 month ago

AlloID is a Transplant Patient-Specific Metagenomic Infectious Disease Test Platform, Furthering CareDx's Innovation in Multi-Modality Surveillance Care AlloID is a Transplant Patient-Specific...

GlobeNewsWire - 1 month ago

CareDx wins a 2-year competitive tender with the French National Blood Service, Établissement Français du Sang CareDx wins a 2-year competitive tender with the French National Blood Service, É...

Seeking Alpha - 1 month ago

CareDx offers organ testing products that are non-invasive alternatives to more invasive traditional tests. The organ transplant market is expected to grow through 2027, creating a tailwind fo...

Zacks Investment Research - 1 month ago

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 1 month ago

Investing in stocks which have outpaced the market in 2020, defying the impacts of the COVID-19 outbreak, and have the potential for greater returns in 2021 is advisable.

Other stocks mentioned: CRWD, MED, MTSI, ZS
Zacks Investment Research - 2 months ago

We discuss four MedTech stocks, CDNA, FLGT, OMI and QDEL that more than doubled in 2020, and are poised to maintain market beating momentum in 2021 on strong fundamentals.

Other stocks mentioned: FLGT, OMI, QDEL
GlobeNewsWire - 2 months ago

Partners with large transplant coalition to expand access to lifesaving medications for kidney transplant patients Partners with large transplant coalition to expand access to lifesaving medic...

Zacks Investment Research - 2 months ago

As of late, it has definitely been a great time to be an investor in CareDx (CDNA).

Zacks Investment Research - 2 months ago

The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.

Other stocks mentioned: HROW, BMXMF, AMEH
Zacks Investment Research - 2 months ago

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 2 months ago

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...

GlobeNewsWire - 3 months ago

Research from Johns Hopkins , U niversity of Maryland, and Cedars Sinai Shows AlloSure May Signal BK Virus Progression in Transplant Patients

GlobeNewsWire - 3 months ago

CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacific Northwest Virtual Kidney Walk CareDx's Chief Marketing Officer Sasha King is the Chair for the Upcoming Pacifi...

Seeking Alpha - 3 months ago

CareDx, Inc. (CDNA) CEO Peter Maag on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

CareDx (CDNA) delivered earnings and revenue surprises of 266.67% and 0.67%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 3 months ago

CareDx, Inc's (CDNA) CEO Peter Maag On Q3 2020 Results - Quick Version Earnings Call Transcript

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...

Zacks Investment Research - 4 months ago

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meeting General nephrologists show a growing interest in AlloSu...

GlobeNewsWire - 4 months ago

CMS believes AlloMap reimbursement process is clinically appropriate for heart transplant patients CMS believes AlloMap reimbursement process is clinically appropriate for heart transplant pat...

GlobeNewsWire - 4 months ago

Virtual events to highlight newest innovation and solutions for HLA labs during ASHI conference Virtual events to highlight newest innovation and solutions for HLA labs during ASHI conference

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization of ...

Zacks Investment Research - 4 months ago

Does CareDx (CDNA) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of...

GlobeNewsWire - 4 months ago

LARGO and The University of Texas Health Science Center at San Antonio publications demonstrate benefits of AlloSure in lung transplant patients LARGO and The University of Texas Health Scienc...

GlobeNewsWire - 4 months ago

Final decision on AlloSure Heart paves the way for HeartCare, the most comprehensive multi-modality tool available to heart transplant patients Final decision on AlloSure Heart paves the way f...

GlobeNewsWire - 5 months ago

AlloCare mobile app is now available to help transplant patients manage their health, communicate efficiently, and stay connected AlloCare mobile app is now available to help transplant patien...

GlobeNewsWire - 5 months ago

AlloSure and AlloSeq cfDNA surveillance tools to be featured along with four virtual symposia at international congress AlloSure and AlloSeq cfDNA surveillance tools to be featured along with ...

GlobeNewsWire - 5 months ago

CareDx appoints key hires in digital services, laboratory operations, business development and market access CareDx appoints key hires in digital services, laboratory operations, business deve...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization...

Seeking Alpha - 6 months ago

CareDx, Inc (CDNA) CEO Peter Maag on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

CareDx (CDNA) delivered earnings and revenue surprises of 166.67% and 17.69%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Patient-focused during COVID-19 pandemic and succeeding Patient-focused during COVID-19 pandemic and succeeding

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization ...

Zacks Investment Research - 6 months ago

Companies across the healthcare sector experience a mixed impact from coronavirus. While some gain traction from a surge in virtual care, the rest suffers demand woes and supply-chain glitches.

Other stocks mentioned: ANTM, CI, MOH, TDOC
GlobeNewsWire - 7 months ago

SOUTH SAN FRANCISCO, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development and commercialization o...

GlobeNewsWire - 7 months ago

Peter Maag is Presenting on AI in Transplant Care at the AAKP and George Washington International Patient Summit Peter Maag is Presenting on AI in Transplant Care at the AAKP and George Washin...

24/7 Wall Street - 7 months ago

It is very possible by now that many adults have had a telehealth conference or checkup.

Other stocks mentioned: CI, DGX, EXAS

About CDNA

CareDx discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, whi... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 17, 2014
CEO
Peter Maag
Employees
306
Stock Exchange
NASDAQ
Ticker Symbol
CDNA
Full Company Profile

Financial Performance

In 2020, CareDx's revenue was $192.19 million, an increase of 51.25% compared to the previous year's $127.07 million. Losses were -$18.71 million, -14.81% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CareDx stock is "Strong Buy." The 12-month stock price forecast is 82.83, which is an increase of 4.50% from the latest price.

Price Target
$82.83
(4.50% upside)
Analyst Consensus: Strong Buy